Cancer drug trial aims to shrink hidden HIV reservoirs
NCT ID NCT07342491
Summary
This early-stage study is testing whether the cancer medication dasatinib can reduce the hidden HIV that persists in the body even during effective treatment. Fourteen adults with well-controlled HIV on long-term therapy will take either dasatinib or a placebo pill for 12 weeks. Researchers will carefully monitor safety and measure if the drug shrinks this hidden viral reservoir, which is a major barrier to curing HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
1401, University of Washington Positive Research CRS
Seattle, Washington, 98104, United States
-
2501, Case CRS
Cleveland, Ohio, 44106, United States
-
Northwestern University CRS (Site # 2701)
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.